IDOSE TR (Travoprost) Patent Expiration, LOE Window & CMS Spending

IDOSE TR (Travoprost) by Glaukos: FDA Orange Book core substance LOE 2031-02-14, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $13,950 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGlaukos
FDA Application & PathwayN218010 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2031-02-14
Last Listed Patent or Exclusivity Date2031-02-14
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($13,950 intro WAC)